Osteoprotegerin, rank and rank ligand

被引:0
|
作者
Kurban, Sevil [1 ]
Mehmetoglu, Idris [1 ]
机构
[1] Selcuk Univ, Meram Tip Fak, Biyokimya Anabilim Dali, TR-42080 Konya, Turkey
关键词
osteoprotegerin; receptor activator of nuclear factor-kappa B; receptor activator of nuclear factor-kappa B ligand; Bone resorption; Immune system; Arterial calcification;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts, leading to bone resorption. Osteoprotegerin is a soluble decoy receptor for the receptor activator of nuclear factor-kappa B ligand thereby inhibiting bone resorption. In addition to providing fundamental insights in bone biology, they may be involved in the immune system, arterial calcification and a number of metabolic bone diseases. In this review, we summarize the roles of receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone metabolism, immune system and arterial calcification and discuss their potential in the treatment of these diseases.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 50 条
  • [1] Osteoprotegerin, RANK, and RANK ligand: The good, the bad, and the ugly in rheumatoid arthritis
    Hofbauer, LC
    Heufelder, AE
    Erben, RG
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (04) : 685 - 687
  • [2] Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
    Hofbauer, L. C.
    ANNALES D ENDOCRINOLOGIE, 2006, 67 (02) : 139 - 141
  • [3] Osteoprotegerin and rank ligand expression in prostate cancer
    Brown, JM
    Corey, E
    Lee, ZD
    True, LD
    Yun, TJ
    Tondravi, M
    Vessella, RL
    UROLOGY, 2001, 57 (04) : 611 - 616
  • [4] Estrogens and the osteoprotegerin/RANK-ligand system
    Hofbauer, LC
    Viereck, V
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) : 1287 - 1287
  • [5] The role of RANK ligand/osteoprotegerin in rheumatoid arthritis
    Geusens, Piet
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2012, 4 (04) : 225 - 233
  • [6] RANK ligand and osteoprotegerin in myeloma bone disease
    Sezer, O
    Heider, U
    Zavrski, I
    Kühne, CA
    Hofbauer, LC
    BLOOD, 2003, 101 (06) : 2094 - 2098
  • [7] Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure
    Ueland, T
    Yndestad, A
    Oie, E
    Florholmen, G
    Halvorsen, B
    Froland, SS
    Simonsen, S
    Christensen, G
    Gullestad, L
    Aukrust, P
    CIRCULATION, 2005, 111 (19) : 2461 - 2468
  • [8] RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation
    Ashcroft, AJ
    Carding, SR
    GUT, 2005, 54 (09) : 1345 - 1346
  • [9] Circulating Osteoprotegerin and Soluble RANK Ligand in Systemic Sclerosis
    Dovio, Andrea
    Data, Valeria
    Carignola, Renato
    Calzolari, Gilberto
    Vitetta, Rosetta
    Ventura, Massimo
    Saba, Laura
    Severino, Adriana
    Angeli, Alberto
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (11) : 2206 - 2213
  • [10] Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland
    Hofbauer, LC
    Kluger, S
    Kühne, CA
    Dunstan, CR
    Burchert, A
    Schoppet, M
    Zielke, A
    Heufelder, AE
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2002, 86 (04) : 642 - 650